RT Journal Article
SR Electronic
T1 DNAm scores for serum GDF15 and NT-proBNP levels associate with a range of traits affecting the body and brain
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.18.23297200
DO 10.1101/2023.10.18.23297200
A1 Gadd, Danni A.
A1 Smith, Hannah M.
A1 Mullin, Donncha
A1 Chybowska, Ola
A1 Hillary, Robert F.
A1 Kimenai, Dorien M
A1 Bernabeu, Elena
A1 Cheng, Yipeng
A1 Fawns-Ritchie, Chloe
A1 Campbell, Archie
A1 Page, Danielle
A1 Taylor, Adele
A1 Corley, Janie
A1 Valdés-Hernández, Maria Del C.
A1 Maniega, Susana Muñoz
A1 Bastin, Mark E.
A1 Wardlaw, Joanna M.
A1 Walker, Rosie M.
A1 Evans, Kathryn L.
A1 McIntosh, Andrew M.
A1 Hayward, Caroline
A1 Russ, Tom
A1 Harris, Sarah E.
A1 Welsh, Paul
A1 Sattar, Naveed
A1 Cox, Simon R.
A1 McCartney, Daniel L.
A1 Marioni, Riccardo E.
YR 2023
UL http://medrxiv.org/content/early/2023/10/19/2023.10.18.23297200.abstract
AB Background Plasma growth differentiation factor 15 (GDF15) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are cardiovascular biomarkers that associate with a range of diseases. Epigenetic scores (EpiScores) for GDF15 and NT-proBNP may provide new routes for risk stratification.Results In the Generation Scotland cohort (N ≥ 16,963), GDF15 levels were associated with incident dementia, ischaemic stroke and type 2 diabetes, whereas NT-proBNP levels were associated with incident ischaemic heart disease, ischaemic stroke and type 2 diabetes (all PFDR < 0.05). Bayesian Epigenome-wide association studies (EWAS) identified 12 and 4 DNA methylation (DNAm) CpG sites associated (Posterior Inclusion Probability [PIP] > 95%) with levels of GDF15 and NT-proBNP, respectively. EpiScores for GDF15 and NT-proBNP that were trained in a subset of the population. The GDF15 EpiScore replicated protein associations with incident dementia, type 2 diabetes and ischaemic stroke in the Generation Scotland test set (Hazard Ratios (HR) range 1.36 – 1.41, PFDR <0.03). The EpiScore for NT-proBNP replicated the protein association with type 2 diabetes, but failed to replicate an association with ischaemic stroke. EpiScores explained comparable variance in protein levels across both the Generation Scotland test set and the external LBC1936 test cohort (R2 range of 5.7-12.2%). In LBC1936, both EpiScores were associated with indicators of poorer brain health. Neither EpiScore was associated with incident dementia in the LBC1936 population.Conclusions EpiScores for serum levels of GDF15 and Nt-proBNP associate with body and brain health traits. These EpiScores are provided as potential tools for disease risk stratification.Competing Interest StatementR.E.M is an advisor to the Epigenetic Clock Development Foundation and has received consultant fees from Optima partners. A.M.M has previously received speakers fees from Illumina and Janssen and research grant funding from The Sackler Trust. R.F.H. has received consultant fees from Illumina and Optima partners. D.A.G. has received consultant fees from and is currently employed in part-time capacity by Optima partners. D.L.M. is currently employed in part-time capacity by Optima partners. PW reports grant income from Roche Diagnostics in relation to and outside of the submitted work as well as grant income from AstraZeneca Boehringer Ingelheim and Novartis outside the submitted work and speaker fees from Novo Nordisk and Raisio outside the submitted work. NS has consulted for Afimmune Amgen AstraZeneca Boehringer Ingelheim Eli Lilly Hanmi Pharmaceuticals Merck Sharp & Dohme Novartis Novo Nordisk Pfizer and Sanofi and received grant support paid to his University from AstraZeneca Boehringer Ingelheim Novartis and Roche Diagnostics outside the submitted work. All other authors declare no competing interest.Funding StatementThis research was funded in whole, or in part, by the Wellcome Trust [104036/Z/14/Z, 108890/Z/15/Z, 221890/Z/20/Z, 218493/Z/19/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission D.A.G. is supported by funding from the Wellcome Trust 4 year PhD in Translational Neuroscience: training the next generation of basic neuroscientists to embrace clinical research [108890/Z/15/Z]. R.F.H is supported through a MRC IEU Short term Fellowship. E.B. and R.E.M are supported by Alzheimers Society major project grant ASPG19b010. Hannah Smith is a student on the Translational Neuroscience PhD Programme and is funded by Wellcome grant [218493/Z/19/Z]. Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). Genotyping and DNAm profiling of the GS samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award STratifying Resilience and Depression Longitudinally (STRADL; Reference 104036/Z/14/Z). The DNAm data assayed for Generation Scotland was partially funded by a 2018 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation (Ref: 27404; awardee: Dr David M Howard) and by a JMAS SIM fellowship from the Royal College of Physicians of Edinburgh (Awardee: Dr Heather C Whalley). Recruitment to the CovidLife study was facilitated by SHARE the Scottish Health Research Register and Biobank. Roche Diagnostics supported this study through provision of free reagents and a grant for measurement of NTproBNP and GDF15 in Generation Scotland. LBC1936 is supported by the Biotechnology and Biological Sciences Research Council, and the Economic and Social Research Council [BB/W008793/1] (which supports S.E.H.), Age UK (Disconnected Mind project), the Milton Damerel Trust, and the University of Edinburgh. S.R.C. is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (221890/Z/20/Z). Methylation typing was supported by Centre for Cognitive Ageing and Cognitive Epidemiology (Pilot Fund award), Age UK, The Wellcome Trust Institutional Strategic Support Fund, The University of Edinburgh, and The University of Queensland. J.M.W., is funded by the UK Dementia Research Institute Ltd which is funded by the Medical Research Council, Alzheimers Society and Alzheimers Research UK Institute (award no. UKDRI Edin002, DRIEdi17/18, and MRC MCPC17113). D.M.K. is supported by a British Heart Foundation Intermediate Basic Science Research Fellowship (FS/IBSRF/23/25161). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All components of Generation Scotland received ethical approval from the NHS Tayside Committee on Medical Research Ethics (REC Reference Number: 05/S1401/89). Generation Scotland has also been granted Research Tissue Bank status by the East of Scotland Research Ethics Service (REC Reference Number: 20-ES-0021), providing generic ethical approval for a wide range of uses within medical research. LBC1936 ethical approval was obtained from the Multicentre Research Ethics Committee for Scotland (Wave 1, MREC/01/0/56), the Lothian Research Ethics Committee (Wave 1, LREC/2003/2/29), and the Scotland A Research Ethics Committee (Waves 2-5, 07/MRE00/58). All participants provided written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe source datasets from the cohorts that were analysed during the current study are not publicly available due to them containing information that could compromise participant consent and confidentiality. Data can be obtained from the data owners. Instructions for accessing Generation Scotland data can be found here: https://www.ed.ac.uk/generation-scotland/for-researchers/access; the GS Access Request Form can be downloaded from this site. Completed request forms must be sent to access@generationscotland.org to be approved by the Generation Scotland Access Committee. According to the terms of consent for Generation Scotland participants access to data must be reviewed by the Generation Scotland Access Committee. Applications should be made to access@generationscotland.org. LBC1936 data are available on request from the Lothian Birth Cohort Study University of Edinburgh https://www.ed.ac.uk/lothian-birth-cohorts/data-access-collaboration. All correspondence and material requests should be sent to Riccardo Marioni at riccardo.marioni@ed.ac.uk. All R code used in analyses is provided at: https://github.com/DanniGadd/EpiScores-GDF15-NT-proBNP. Latent Curve Growth Model (LCGM) LBC cognitive code that was adapted for these analyses is also available at: https://www.ed.ac.uk/lothian-birth-cohorts/summary-data-resources. https://github.com/DanniGadd/EpiScores-GDF15-NT-proBNP https://www.ed.ac.uk/lothian-birth-cohorts/summary-data-resources. https://www.ed.ac.uk/generation-scotland/for-researchers/access https://www.ed.ac.uk/lothian-birth-cohorts/data-access-collaboration BMIBody mass indexCIConfidence intervalCOJOConditional and joint analysesCOVID-19Coronavirus disease 2019CpGCytosine-phosphate-guanineDNAmDNA methylationEpiScoreEpigenetic scoreEWASEpigenome-wide association studyFDRFalse discovery rateGCTAGenome-wide Complex Trait AnalysisGDF15Plasma growth differentiation factor 15GWASGenome-wide association studyHbA1cGlycated haemoglobinHRHazard ratioICDInternational Classification of Diseases codesIHDIschaemic heart diseaseIgGImmunoglobulin GMRIMagnetic resonance imagingNT-proBNPN-terminal pro-B-type natriuretic peptideLBC1936The Lothian Birth Cohort of 1936ORodds ratioPHProportional hazardsPIPPosterior inclusion probabilitypQTLProtein quantitative trait lociPRSPolygenic risk scoreSDStandard deviation SE - Standard errorSEMStructural equation model